Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MREO |
---|---|---|
09:32 ET | 10259 | 3.45 |
09:34 ET | 9300 | 3.44 |
09:36 ET | 6397 | 3.4 |
09:38 ET | 10350 | 3.42 |
09:39 ET | 2672 | 3.46 |
09:41 ET | 450 | 3.445 |
09:43 ET | 400 | 3.465 |
09:45 ET | 200 | 3.465 |
09:48 ET | 300 | 3.48 |
09:50 ET | 16425 | 3.5 |
09:52 ET | 1888 | 3.48 |
09:54 ET | 500 | 3.49 |
09:56 ET | 12900 | 3.53 |
09:57 ET | 6900 | 3.51 |
09:59 ET | 23414 | 3.505 |
10:01 ET | 500 | 3.52 |
10:03 ET | 1630 | 3.525 |
10:06 ET | 3550 | 3.52 |
10:08 ET | 600 | 3.515 |
10:10 ET | 1600 | 3.485 |
10:12 ET | 1800 | 3.5 |
10:14 ET | 1750 | 3.505 |
10:15 ET | 3762 | 3.525 |
10:17 ET | 2395 | 3.505 |
10:19 ET | 2500 | 3.475 |
10:21 ET | 1300 | 3.465 |
10:24 ET | 10110 | 3.445 |
10:26 ET | 6811 | 3.455 |
10:28 ET | 1100 | 3.465 |
10:30 ET | 1000 | 3.465 |
10:32 ET | 1100 | 3.465 |
10:33 ET | 1840 | 3.475 |
10:35 ET | 2808 | 3.475 |
10:37 ET | 700 | 3.475 |
10:39 ET | 500 | 3.47 |
10:42 ET | 1600 | 3.48 |
10:44 ET | 350 | 3.475 |
10:46 ET | 600 | 3.485 |
10:48 ET | 1696 | 3.49 |
10:50 ET | 600 | 3.485 |
10:51 ET | 400 | 3.485 |
10:53 ET | 11900 | 3.485 |
10:55 ET | 1300 | 3.475 |
10:57 ET | 4430 | 3.475 |
11:00 ET | 1500 | 3.475 |
11:02 ET | 1000 | 3.47 |
11:04 ET | 800 | 3.475 |
11:06 ET | 4285 | 3.495 |
11:08 ET | 3400 | 3.475 |
11:09 ET | 7000 | 3.475 |
11:11 ET | 1358 | 3.475 |
11:13 ET | 800 | 3.475 |
11:15 ET | 200 | 3.475 |
11:18 ET | 650 | 3.474 |
11:20 ET | 1602 | 3.49 |
11:22 ET | 356 | 3.4899 |
11:24 ET | 1800 | 3.485 |
11:26 ET | 1300 | 3.485 |
11:27 ET | 1200 | 3.49 |
11:29 ET | 1511 | 3.475 |
11:31 ET | 9151 | 3.465 |
11:33 ET | 2325 | 3.475 |
11:36 ET | 500 | 3.475 |
11:38 ET | 1100 | 3.475 |
11:40 ET | 600 | 3.475 |
11:42 ET | 484 | 3.475 |
11:44 ET | 1000 | 3.475 |
11:45 ET | 16933 | 3.45 |
11:47 ET | 400 | 3.45 |
11:49 ET | 1100 | 3.455 |
11:51 ET | 3300 | 3.465 |
11:54 ET | 1100 | 3.465 |
11:56 ET | 900 | 3.465 |
11:58 ET | 847 | 3.46 |
12:00 ET | 4677 | 3.455 |
12:02 ET | 300 | 3.455 |
12:03 ET | 1000 | 3.455 |
12:05 ET | 2568 | 3.46 |
12:09 ET | 3214 | 3.465 |
12:18 ET | 300 | 3.465 |
12:20 ET | 2293 | 3.475 |
12:21 ET | 460 | 3.48 |
12:23 ET | 830 | 3.475 |
12:25 ET | 1400 | 3.475 |
12:27 ET | 800 | 3.47 |
12:30 ET | 200 | 3.475 |
12:32 ET | 100 | 3.475 |
12:34 ET | 600 | 3.475 |
12:36 ET | 500 | 3.475 |
12:38 ET | 1557 | 3.49 |
12:39 ET | 3039 | 3.485 |
12:41 ET | 4100 | 3.475 |
12:43 ET | 300 | 3.475 |
12:45 ET | 5250 | 3.475 |
12:48 ET | 4016 | 3.475 |
12:50 ET | 9361 | 3.475 |
12:52 ET | 2340 | 3.47 |
12:54 ET | 2700 | 3.47 |
12:56 ET | 2600 | 3.475 |
12:57 ET | 700 | 3.475 |
12:59 ET | 4500 | 3.465 |
01:01 ET | 6817 | 3.475 |
01:03 ET | 2400 | 3.475 |
01:06 ET | 3000 | 3.475 |
01:08 ET | 400 | 3.475 |
01:10 ET | 4600 | 3.45 |
01:12 ET | 8588 | 3.445 |
01:14 ET | 200 | 3.445 |
01:15 ET | 2600 | 3.445 |
01:17 ET | 900 | 3.445 |
01:19 ET | 700 | 3.445 |
01:21 ET | 400 | 3.445 |
01:24 ET | 2756 | 3.445 |
01:26 ET | 400 | 3.445 |
01:28 ET | 1500 | 3.445 |
01:30 ET | 3457 | 3.445 |
01:32 ET | 400 | 3.445 |
01:33 ET | 600 | 3.445 |
01:35 ET | 500 | 3.445 |
01:37 ET | 5054 | 3.45 |
01:39 ET | 400 | 3.445 |
01:42 ET | 1513 | 3.45 |
01:44 ET | 950 | 3.45 |
01:46 ET | 800 | 3.45 |
01:48 ET | 4648 | 3.453 |
01:50 ET | 4465 | 3.455 |
01:51 ET | 192873 | 3.4599 |
01:53 ET | 6042 | 3.43 |
01:55 ET | 12538 | 3.41 |
01:57 ET | 11301 | 3.425 |
02:02 ET | 6635 | 3.4145 |
02:04 ET | 600 | 3.415 |
02:06 ET | 3376 | 3.425 |
02:08 ET | 3641 | 3.435 |
02:09 ET | 100 | 3.43 |
02:11 ET | 300 | 3.44 |
02:13 ET | 1948 | 3.435 |
02:15 ET | 305 | 3.435 |
02:18 ET | 2456 | 3.445 |
02:22 ET | 4074 | 3.46 |
02:24 ET | 525 | 3.465 |
02:26 ET | 4100 | 3.465 |
02:27 ET | 4164 | 3.46 |
02:29 ET | 1964 | 3.475 |
02:33 ET | 1474 | 3.48 |
02:38 ET | 100 | 3.475 |
02:40 ET | 200 | 3.475 |
02:42 ET | 800 | 3.475 |
02:44 ET | 3560 | 3.48 |
02:45 ET | 500 | 3.485 |
02:47 ET | 400 | 3.485 |
02:49 ET | 2102 | 3.5 |
02:51 ET | 2495 | 3.5 |
02:54 ET | 2327 | 3.5 |
02:56 ET | 1394 | 3.5 |
02:58 ET | 1229 | 3.5 |
03:00 ET | 300 | 3.5 |
03:02 ET | 1300 | 3.5 |
03:03 ET | 1100 | 3.5 |
03:05 ET | 2279 | 3.4975 |
03:07 ET | 10879 | 3.49 |
03:09 ET | 200 | 3.495 |
03:12 ET | 300 | 3.495 |
03:14 ET | 289 | 3.49 |
03:16 ET | 2340 | 3.49 |
03:18 ET | 400 | 3.495 |
03:20 ET | 300 | 3.495 |
03:21 ET | 800 | 3.495 |
03:23 ET | 1800 | 3.495 |
03:25 ET | 11859 | 3.5 |
03:27 ET | 700 | 3.495 |
03:30 ET | 500 | 3.495 |
03:32 ET | 2029 | 3.495 |
03:34 ET | 300 | 3.495 |
03:36 ET | 11431 | 3.47 |
03:38 ET | 6790 | 3.475 |
03:39 ET | 3600 | 3.47 |
03:41 ET | 1100 | 3.475 |
03:43 ET | 3397 | 3.47 |
03:45 ET | 3100 | 3.47 |
03:48 ET | 6400 | 3.475 |
03:50 ET | 3200 | 3.475 |
03:52 ET | 3100 | 3.475 |
03:54 ET | 6784 | 3.475 |
03:56 ET | 6647 | 3.47 |
03:57 ET | 15141 | 3.475 |
03:59 ET | 17586 | 3.48 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Mereo BioPharma Group PLC | 533.3M | -11.1x | --- |
AnaptysBio Inc | 651.5M | -4.0x | --- |
SS Innovations International Inc | 683.0M | -32.1x | --- |
Immunome Inc | 721.4M | -2.2x | --- |
Stoke Therapeutics Inc | 727.1M | -5.5x | --- |
Dianthus Therapeutics Inc | 695.3M | -7.8x | --- |
Mereo BioPharma Group plc is a biopharmaceutical company. It is focused on the development of therapeutics for rare diseases. It has developed a portfolio of clinical-stage product candidates. The Company has two rare disease product candidates: setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for the treatment of severe alpha-1-antitrypsin deficiency-associated lung disease (AATD-LD) and bronchiolitis obliterans syndrome (BOS). It also has two oncology product candidates in clinical development. It also includes Etigilimab, an antibody against TIGIT (T-cell immunoreceptor with Ig and ITIM domains). Its non-core partnered programme, Navicixizumab, is a bispecific antibody that inhibits delta-like ligand 4 (DLL4) and vascular endothelial growth factor (VEGF). Its non-core programs available for partnership include Acumapimod and Leflutrozole. Acumapimod is a p38 MAP kinase inhibitor therapy for treatment during severe acute exacerbations of COPD (AECOPD).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $533.3M |
---|---|
Revenue (TTM) | $10.0M |
Shares Outstanding | 152.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.88 |
EPS | $-0.31 |
Book Value | $0.44 |
P/E Ratio | -11.1x |
Price/Sales (TTM) | 53.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -416.58% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.